Trial Profile

A randomized, open-label study of the effect of MabThera alone and in combination with Roferon-A on time to treatment failure in patients with follicular or other low-grade lymphoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon alpha-2a (Primary) ; Rituximab (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma
Focus Registrational; Therapeutic Use
Sponsors Roche

01 Oct 2020 Results from ML16865 and other trial analysing the long term prognostic relevance of pre treatment absolute blood counts of lymphocytes with subsets and monocytes in follicular lymphoma patients, published in the Annals of Hematology
10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
05 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01609010).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com